Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 18:14:1405380.
doi: 10.3389/fonc.2024.1405380. eCollection 2024.

Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer

Hongyan Li  1 , Lina Xu  1 , Hongshun Cao  1 , Tianyi Wang  1 , Siwen Yang  1 , Yixin Tong  1 , Linlin Wang  2 , Qiang Liu  1
Affiliations
Review

Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer

Hongyan Li et al. Front Oncol. .

Abstract

Lung cancer persistently leads as the primary cause of morbidity and mortality among malignancies. A notable increase in the prevalence of lung adenocarcinoma has become evident in recent years. Although targeted therapies have shown in treating certain subsets of non-small cell lung cancers (NSCLC), a significant proportion of patients still face suboptimal therapeutic outcomes. Neuregulin-1 (NRG1), a critical member of the NRG gene family, initially drew interest due to its distribution within the nascent ventricular endocardium, showcasing an exclusive presence in the endocardium and myocardial microvessels. Recent research has highlighted NRG1's pivotal role in the genesis and progression across a spectrum of tumors, influencing molecular perturbations across various tumor-associated signaling pathways. This review provides a concise overview of NRG1, including its expression patterns, configuration, and fusion partners. Additionally, we explore the unique features and potential therapeutic strategies for NRG1 fusion-positive occurrences within the context of NSCLC.

Keywords: future prospects; neuregulin-1 (NRG1) fusion; non-small cell lung cancer (NSCLC); pathogenesis; treatment progress.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. (2021) 71:7–33. - PubMed
    1. Cierpiał-Wolan M, Wójcik S, Gawełko J, Czarnota M. Does the level of air pollution affect the incidence of lung adenocarcinoma in south-eastern Poland? Int J Environ Res Public Health. (2023) 20:3177. - PMC - PubMed
    1. Rosas D, Raez LE, Russo A, Rolfo C. Neuregulin 1 gene (NRG1). A potentially new targetable alteration for the treatment of lung cancer. Cancers (Basel). (2021) 13:5038. - PMC - PubMed
    1. Werr L, Plenker D, Dammert MA, Lorenz C, Brägelmann J, Tumbrink HL, et al. . CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Mol Cancer Ther. (2022) 21:821–30. - PMC - PubMed
    1. Severson E, Achyut BR, Nesline M, Pabla S, Previs RA, Kannan G, et al. . RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers. J Mol Diagn. (2023) 25:454–66. - PubMed

LinkOut - more resources